-
-
At this point there’s probably a lot more clinical safety data from remdesivir, over years and many many patients. That sort of thing might be very costly and slow to replicate, for not stellar performing drug might not be worth it.
-
If I'm reading this correctly, remdesivir almost immediately and completely metabolizes into GS-441524 anyway, so it can't possibly be *less* safe. But that doesn't count as clinical safety data, so we're forbidden to act on it, thus "frozen in place".
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.